Macrophage Differentiation and Polarization into an M2-Like Phenotype using a Human Monocyte-Like THP-1 Leukemia Cell Line
August 2nd, 2021
M2-like tumor-associated macrophages (TAM) are associated with tumor progression and poor prognosis in cancer. This protocol serves as a detailed guide to reproducibly differentiate and polarize THP-1 monocyte-like cells into M2-like macrophages within 14 days. This model is the basis to investigate the anti-inflammatory effects of TAM within the tumor microenvironment.
Anti-inflammatory tumor associated macrophages are linked to progression and poor prognosis in cancer. This protocol is a guide to differentiate and polarize THP-1 monocyte-like cells into M2-like macrophages within 14 days. Currently there is no established model for anti-inflammatory THP-1 polarization.
This protocol uses adequate resting periods and a prolonged polarization process to create a distinct M2-like macrophage subtype. Tumor development, for example, in colon cancer and tissue remodeling, are controlled by anti-inflammatory macrophages. Among studies investigating their function, standardized creation of a distinct M2-like subtype ensures reproducible findings.
Begin by setting a timer for 150 seconds. Remove the frozen vial containing the THP-1 cell line from the liquid nitrogen and thaw the vial immediately at 37 degrees Celsius in a clean water bath, starting the timer as soon as the vial is put into the water bath. Loosen the cap to release the pressure built up due to the thawing process, ensuring that the tube opening does not contact the water to avoid contamination.
Thaw the cell suspension until an ice chip about four millimeters in size is left within the vial and proceed to the next step immediately. Transfer the liquid phase of the cell suspension to a 15 milliliter tube containing nine milliliters of warm growth media. Then transfer one milliliter of this warm medium cell suspension into the THP-1 vial and back to the 15 milliliter tube to melt the remaining ice chip, and flush the vial to ensure no cells are left behind.
Mix the suspension gently by pipetting it up and down with a one milliliter pipette. Remove approximately 10 microliters of the sample to count the cells for viability using trypan blue. The cells with clear cytoplasm are viable, a blue cytoplasm indicates cell death.
While counting, spin down the warm cell suspension at 200 times G for seven minutes at 37 degrees Celsius. Remove the supernatant completely and resuspend the cells in growth medium to achieve a cell density of 500, 000 cells per milliliter. Mix the suspension gently and transfer 22 milliliters into T75 cell culture flasks each.
Store the flasks upright in an incubator at 37 degrees Celsius with a 5%carbon dioxide concentration and exchange the growth media every three to four days. Prepare the cell suspension to seed the cells at a density of 300, 000 per milliliter per well into 24-well cell culture plates. Mix the medium gently and a prepare aliquots of 26 milliliters in 50 milliliter tubes.
Transfer one milliliter of the cell-containing medium into each well of a 24-well plate. Mix the media gently by pipetting it up and down between transfers. Keep the freshly prepared working solution of PMA on ice and add 100 nanograms of PMA per well.
Incubate the plates in the incubator without any further treatment for 72 hours. After 72 hours, remove the growth medium and replace it with one milliliter of fresh growth medium, ensuring not to touch the bottom of the wells with pipette tips. Let the cells rest for another 96 hours in the incubator.
Remove the growth medium and replace it with one milliliter of fresh growth medium. Add 20 nanograms of interleukin 4 and 20 nanograms of interleukin 13 per well. Then let the cells rest for 48 hours in the incubator.
Repeat the whole process after 48 hours and let the cells rest for another 48 hours in the incubator. Remove the growth medium and replace it with one milliliter of fresh growth medium. Then let the cells rest for 48 hours in the incubator.
Remove the warm cell medium from each well and replace it with a one milliliter mixture of ice cold PBS without calcium and magnesium and 5%FBS. Then immediately place the cell plate on ice for 45 minutes. After 45 minutes on ice, scrape off the cells using mini cell scrapers.
Gently transfer the detached macrophages to cold PBS and 5%FBS in a 15 milliliter tube kept on ice. The macrophages derived from the polarization method show the expression of CD14, as well as CD11b markers. The monocyte and macrophage markers CD14 and CD11b were expressed in 70.9%and 74.7%of cells, respectively.
Cells showed low surface levels of the M1-like marker CD80 in 0.2%of cells, and high surface levels of the M2-like marker CD206 in 62.6%of cells. As THP-1 cells in medium tend to sink to the bottom of a vial and are easy to activate through mechanical stress, gentle mixing and handling of the cells is important. M2-like macrophages are reproducibly created, and have been characterized using QR-TPCR, ELISA, and flow cytometry.
This is the basis for investigating anti-inflammatory mechanisms in cancer development or tissue remodeling.
View the full transcript and gain access to thousands of scientific videos
Overview
This protocol provides a comprehensive guide for differentiating and polarizing THP-1 monocyte-like cells into M2-like macrophages within 14 days. M2-like tumor-associated macrophages (TAM) are linked to tumor progression and poor prognosis in cancer, making this model essential for studying their anti-inflammatory effects in the tumor microenvironment.
Key Study Components
Area of Science
- Neuroscience
- Cell Biology
- Cancer Research
Background
- M2-like TAM are associated with cancer progression.
- There is a lack of established models for anti-inflammatory THP-1 polarization.
- Standardized creation of distinct macrophage subtypes is crucial for reproducible research.
- Anti-inflammatory macrophages play a role in tumor development and tissue remodeling.
Purpose of Study
- To provide a reproducible protocol for generating M2-like macrophages.
- To investigate the role of TAM in the tumor microenvironment.
- To enhance understanding of anti-inflammatory mechanisms in cancer.
Methods Used
- Differentiation of THP-1 monocytes into macrophages.
- Prolonged polarization process to achieve M2-like phenotype.
- Incorporation of resting periods during the protocol.
- Standardization of methods to ensure reproducibility.
Main Results
- Successful differentiation and polarization of THP-1 cells into M2-like macrophages.
- Establishment of a reliable model for studying TAM functions.
- Insights into the anti-inflammatory roles of M2-like macrophages in cancer.
- Potential implications for therapeutic strategies targeting TAM.
Conclusions
- The protocol enables reproducible generation of M2-like macrophages.
- Understanding TAM functions can inform cancer treatment approaches.
- Further research is needed to explore the therapeutic potential of targeting M2-like macrophages.
Frequently Asked Questions
Executive Industry Relevance
This protocol addresses a critical gap in immuno-oncology research by providing a standardized method to generate M2-like tumor-associated macrophages from THP-1 cells, enabling reproducible investigation of immunosuppressive mechanisms in cancer. The model supports target validation and mechanistic de-risking for therapies aimed at modulating macrophage polarization in the tumor microenvironment. By establishing a reliable M2-like phenotype, it enhances predictive confidence in preclinical studies linking TAM function to tumor progression and tissue remodeling.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of M2-like macrophage phenotype as a therapeutic target in cancer progression.
- Operational Value: Provides a consistent cellular model for validating targets involved in macrophage polarization pathways.
Screening & Assay Development
- Scientific Value: Generates a standardized macrophage population for screening immunomodulatory compounds affecting M2 marker expression.
- Operational Value: Supports assay development with defined endpoints such as CD206 and CD80 expression levels for compound profiling.
Translational & Preclinical Research
- Scientific Value: Facilitates preclinical evaluation of agents that modulate TAM polarization in tumor-like contexts.
- Operational Value: Enables longitudinal assessment of M2-like macrophage stability and function over the 14-day polarization timeline.
Pipeline & Workflow Integration
The method integrates into early discovery workflows by supplying a validated macrophage model for target engagement and functional screening prior to lead optimization.
- Discovery Biology: Supports hypothesis testing on M2-polarizing signals and their role in tumor-promoting inflammation.
- Screening: Delivers reproducible macrophage preparations for quantitative assessment of compound effects on polarization markers.
- Analytics: Enables flow cytometry, qRT-PCR, and ELISA readouts to measure CD206, CD80, CD14, and CD11b as polarization indicators.
- Translational Research: Models M2-like TAM involvement in tumor progression and tissue remodeling for preclinical continuity.
- Enterprise Reuse: Establishes a reusable platform for immunology and oncology teams studying macrophage-mediated drug resistance.
Operational & Enterprise Impact
- Scientific Value: Reduces mechanistic ambiguity in TAM-related phenotypes through standardized M2-like macrophage generation.
- Operational Value: Ensures reproducibility across laboratories via defined differentiation, resting, and polarization intervals.
- Strategic Value: Improves go/no-go decisions by providing reliable preclinical data on macrophage-targeted interventions.
- Portfolio Impact: Enables risk-adjusted prioritization of immunomodulatory candidates based on consistent M2-like macrophage responses.
Implementation Considerations
- Requires expertise in primary cell culture, flow cytometry, and cytokine handling.
- Depends on access to incubators, biosafety cabinets, and equipment for cell counting and viability assessment.
- Necessitates standardization of PMA, IL-4, and IL-13 dosing and timing across users.
- Involves adaptation considerations when translating findings to primary human monocytes or in vivo models.
- Includes practical limitations such as donor variability in primary cells and the need for aseptic technique during extended culture.
Biopharma FAQs
Chapters in this video
0:05
Introduction
0:56
Culturing and Maintenance of THP‐1 Monocyte-like Cells
2:59
Seeding of THP‐1 cells and Differentiation into M0 Macrophages
4:01
Polarization of M0 Macrophages into M2‐like Macrophages
4:39
Detaching and Harvesting Macrophages for Flow Cytometry
5:14
Results: Macrophage Differentiation and Polarization into an M2‐Like Phenotype
5:56
Conclusion
